[Featured Stock] Cellumed Surges for 2 Consecutive Days... "Following Completion of Celluderm Peel Development, Accelerating 'Zen' Development"

Cellumed is showing strong performance. The news that the company has completed the development of the new acellular dermal matrix (ADM) injectable skin graft product 'CELLUDERM FILL' and is nearing the completion of 'CELLUDERM GEN' development appears to have had an impact.

As of 9:11 AM on the 4th, Cellumed was trading at 2,295 KRW, up 325 KRW (16.50%) compared to the previous trading day.

Cellumed announced that the development of CELLUDERM FILL was completed faster than expected, allowing the company to fully concentrate on the development of CELLUDERM GEN. Accordingly, the completion timeline for CELLUDERM GEN is expected to be significantly advanced. CELLUDERM GEN aims to complete development as early as the end of this year or the beginning of next year.

CELLUDERM GEN is an injectable product similar to CELLUDERM FILL. However, it is characterized by a different mixing ratio of purified water or biocompatible polymer carriers with finely powdered acellular dermal matrix. Unlike CELLUDERM FILL, which is mainly used in surgeries such as breast reconstruction, CELLUDERM GEN is intended for different purposes, and upon completion of development, its indications are expected to expand significantly.